Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | USP14 | P54578 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847911 | 0.91 | CTSK (0.57) | KCNA3CTSKBTKDRD2CCR5 | |
| SCHEMBL8256718 | 0.91 | CTSK (0.57) | KCNA3CTSKBTKDRD2CCR5 | |
| SCHEMBL10006308 | 0.91 | CTSK (0.57) | KCNA3CTSKBTKDRD2CCR5 | |
| SCHEMBL7586943 | 0.87 | CTSK (0.51) | KCNA3CTSKBTKUSP14DRD2 | |
| SCHEMBL620491 | 0.85 | CTSK (0.50) | KCNA3CTSKBTKUSP14DRD2 | |
| SCHEMBL26661838 | 0.85 | KCNA3 (0.61) | KCNA3CTSKBTKDRD2CCR5 | |
| SCHEMBL15373110 | 0.85 | KCNA3 (0.52) | KCNA3CTSKBTKUSP14DRD2 | |
| SCHEMBL18551557 | 0.85 | BTK (0.45) | KCNA3CTSKBTKUSP14DRD2 | |
| SCHEMBL22399970 | 0.85 | BTK (0.45) | KCNA3CTSKBTKUSP14DRD2 | |
| SCHEMBL18551138 | 0.85 | BTK (0.45) | KCNA3CTSKBTKUSP14DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20040087622-A1 | Benzamide derivative and medicament containing the same | KATO HIDEO (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6638951-B1 | Medicament has excellent enhancing action on gastrointestinal tract motility, and is orally available with reduced side effects, the agent for therapeutic treatment of digestive diseases, an agent for improving function of gastrointestinal | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1149832-B1 | BENZAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME | HOKURIKU PHARMACEUTICAL (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1149832-A1 | BENZAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087622-A1 | Benzamide derivative and medicament containing the same | SLC10A2, FABP2, HDAC6 | KCNA3 553/4885CTSK 713/4885BTK 3162/4885 |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | KCNA3 3663/4885CTSK 1058/4885BTK 2004/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | KCNA3 3529/4885CTSK 1492/4885BTK 1512/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | KCNA3 1535/4885CTSK 3078/4885BTK 1599/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | KCNA3 3663/4885CTSK 1058/4885BTK 2004/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | KCNA3 3969/4885CTSK 798/4885BTK 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.